Gabapentin treatment for alcohol dependence: a randomized clinical trial.

ABSTRACT:

Importance

Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.

Objective

To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.

Design, participants and setting

A 12-week, double-blind, placebo-controlled, randomized dose-ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.

Interventions

Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) a

SUBMITTER: Mason BJ 

PROVIDER: S-EPMC3920987 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature